Salem Investment Counselors’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.86K Sell
591
-190
-24% -$1.59K ﹤0.01% 991
2026
Q1
$4.79K Buy
+781
New +$6.5K ﹤0.01% 974
2025
Q4
Sell
-651
Closed -$9.49K 588
2025
Q3
$9.49K Hold
651
﹤0.01% 895
2025
Q2
$7.32K Hold
651
﹤0.01% 894
2025
Q1
$3.71K Sell
651
-18,412
-97% -$188K ﹤0.01% 964
2024
Q4
$187K Sell
19,063
-449
-2% -$3.85K 0.01% 373
2024
Q3
$159K Sell
19,512
-50,995
-72% -$511K ﹤0.01% 396
2024
Q2
$943K Sell
70,507
-48,458
-41% -$1.45M 0.03% 206
2024
Q1
$5.52M Buy
118,965
+62,486
+111% +$3.23M 0.18% 82
2023
Q4
$3.82M Buy
56,479
+6,770
+14% +$415K 0.13% 101
2023
Q3
$3.6M Buy
49,709
+10,054
+25% +$804K 0.14% 99
2023
Q2
$2.95M Buy
39,655
+4,232
+12% +$251K 0.11% 108
2023
Q1
$1.88M Buy
35,423
+11,054
+45% +$700K 0.08% 131
2022
Q4
$1.65M Buy
24,369
+408
+2% +$37.5K 0.07% 140
2022
Q3
$2.99M Buy
23,961
+21,484
+867% +$2.56M 0.14% 101
2022
Q2
$236K Buy
+2,477
New +$302K 0.01% 306

Other funds holding DNA

Salem Investment Counselors's DNA Position: Q2 2026 in Review

Salem Investment Counselors reduced its Ginkgo Bioworks (DNA) stake by 24% in Q2 2026, selling an estimated $1.59K and leaving 591 shares worth $5.86K. The position accounts for ﹤0.01% of the portfolio, ranked #991.

Salem Investment Counselors first reported a position in DNA in Q2 2022 and has held it in 16 quarters since. The position peaked at $5.52M in Q1 2024. 36 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Salem Investment Counselors held 591 shares of Ginkgo Bioworks worth $5.86K as of Q2 2026.
  • Salem Investment Counselors sold 190 Ginkgo Bioworks shares in Q2 2026, an estimated $1.59K.
  • Ginkgo Bioworks made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #991 holding.
  • Salem Investment Counselors first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 16 quarters since.
  • Salem Investment Counselors's Ginkgo Bioworks position peaked at $5.52M in Q1 2024.
  • 36 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.